Comparison · September 2026
NAD+ injection vs NAD+ IV
These are two ways of presenting the body with a molecule it takes apart before any cell uses it, and neither route has the outcome evidence the category is sold on.
Boards for the compounds on this page: NAD+.
At a glance
| Dimension | NAD+ injection | NAD+ IV infusion |
|---|---|---|
| What it is | A compounded NAD+ preparation given by injection under the skin or into muscle, usually at home. | A compounded NAD+ preparation delivered into a vein over a clinic session. |
| How it is given | Self-administered from a vial supplied by a telehealth provider or clinic. | Administered in a clinic or by a mobile infusion service, with staff present. |
| What reaches the cell | Not NAD+ itself. It is broken down outside cells and the fragments are taken up and rebuilt inside. | The same. A vein is a faster way into the bloodstream, not a way into a cell. |
| What the human evidence covers | Thin. Most of what is claimed for this route is inferred from the intravenous work rather than measured directly. | Small studies, largely examining what happens to the molecule after it goes in rather than whether people do better. |
| Evidence grade | Limited evidence — the category grade, which is earned by oral precursors, not by this route. | Limited evidence — same category grade, same caveat. |
| Regulatory position | A compounded preparation rather than an FDA-approved drug. The rules governing it are unsettled. | Also compounded rather than FDA-approved, and the same rules are unsettled. |
| What buyers usually get sold | Convenience — the same promise as the drip without the clinic session. | Energy, brain fog, cognitive performance, athletic recovery, and support for withdrawal and addiction recovery. |
Evidence grade
NAD+ injection
NAD+ IV infusion
Where a compliant provider sells this today
NAD+
Trellis Vitality ranks highest of 14 providers on this board. $129/mo — per month, protocol
Trellis Vitality is not a paid partner; this link may earn a commission if that changes. Full disclosure.
Visit Trellis Vitality See the full NAD+ boardThe short answer
Neither route delivers NAD+ into your cells, because nothing does. NAD+ is a large, charged molecule, and cells do not absorb it whole. Outside the cell it is broken down by surface enzymes into smaller pieces, and those pieces are taken up and used to rebuild NAD+ inside.
Once that is clear, the comparison changes shape. Putting NAD+ into a vein raises the concentration of NAD+ and its breakdown products in the blood. The cell then does what it was always going to do with the fragments. An injection does the same thing more slowly.
So this is not a choice between a strong version and a weak one. It is a choice between two ways of presenting the body with material it is going to dismantle either way, and neither has the outcome evidence the category is marketed on.
What each route has actually been studied for
The human work on intravenous NAD+ has been small. Most of it examined what happens to the molecule after it goes in: how blood levels move, how quickly it is broken down, where the fragments turn up. That is pharmacokinetics. It is a legitimate first step and it is not evidence of clinical benefit.
Injectable NAD+ sold for use outside a clinic has less than that. The published human literature specific to this route is thin, and what is claimed for it is largely inferred from the intravenous work plus the general pharmacology of the molecule.
An inference from another route is a chain of reasoning, not a finding. When a product’s case rests on one, that is worth saying plainly, because otherwise the evidence behind the rest of the category gets quietly borrowed by everything in it.
The grade here was earned somewhere else
NAD+ is graded limited evidence as a category, and that grade is real. It rests on the oral precursors — most commonly nicotinamide riboside — which have been through repeated human trials showing that taking them raises measurable NAD+ levels in blood in a dose-related way.
That is the strongest replicated human finding anywhere in this category. It is also a finding about capsules.
Both routes on this page carry the category grade, and neither one earned it. A reader should not read a category-level grade as an endorsement of the most heavily marketed item on a clinic menu. The asymmetry between what the grade rests on and what is being sold is the single most useful thing to take from this comparison.
What the drip’s tolerability tells you about the pharmacology
Infusing NAD+ quickly commonly produces chest tightness, flushing, nausea and abdominal cramping. This is why these drips are run slowly, and clinics generally describe it openly rather than hiding it.
That is not a safety verdict and it is not presented as one. It is a well-known characteristic of the route.
It does tell you something useful. The body reacts noticeably to this material rather than quietly absorbing it, which is a poor fit with the mental picture of a nutrient topping up a tank. An injection avoids the session, and it does not change what the molecule is or what happens to it.
What is being claimed, and what supports it
Intravenous NAD+ is marketed for fatigue, brain fog, cognitive performance, athletic recovery, and — most aggressively — as support for withdrawal and addiction recovery. Those are serious claims about serious problems.
No body of adequately controlled outcome trials has been published for those uses. The small studies that exist are not that body of work, and pharmacokinetic studies are not a substitute for one.
The injectable route inherits the same claim set, generally with the session removed from the pitch. It inherits the missing evidence too, and it has less direct human data behind it than the route it borrows from.
Where the regulatory question sits
Injectable and intravenous NAD+ preparations are compounded products rather than FDA-approved drugs. The rules governing them are unsettled, and no outcome, timeline or likelihood is asserted here for either route.
A regulatory position moves on its own schedule, and a summary written into a comparison drifts out of date the moment the record changes. The dated record lives on the compound status page, and that is where the current position is stated.
The part a reader can use is what compounded means. The preparation has not been reviewed by the FDA for safety, effectiveness or manufacturing quality, whatever a given pharmacy’s own standards are. That describes the review pathway. It is not an allegation about any specific pharmacy or clinic.
How the grades were set
Both routes carry the category grade of limited evidence, and they carry it for the same reason: the biochemistry of NAD+ is settled and uncontested, and the human pharmacology in the category is genuine.
The grade does not distribute evenly, and nothing here pretends otherwise. The replicated human data belongs to oral precursors. Intravenous NAD+ has small studies mostly about the molecule’s fate in the body. The injectable route has less published work than either.
What would raise the grade for either route is not more biomarker work. It is trials measuring whether people function better, in the population being sold the product, against a placebo, over a period long enough to matter.
Key takeaways
- NAD+ is not absorbed into cells intact — it is broken down outside the cell and rebuilt inside.
- An infusion is a faster route into the bloodstream, not a route into a cell.
- The published human work on intravenous NAD+ is small and mostly about the molecule’s fate, not about outcomes.
- Injectable NAD+ has thinner direct evidence still, and borrows its case from the intravenous route.
- The limited grade in this category is earned by oral precursors, and neither injectable route earned it.
Frequently asked questions
Is an NAD+ IV stronger than an NAD+ injection?
Not in the way the menu implies. NAD+ is not absorbed into cells intact. It is broken down outside the cell by surface enzymes, and the fragments are taken up and rebuilt into NAD+ inside. So an infusion raises blood levels of NAD+ and its breakdown products faster than an injection does, but it does not put NAD+ into a cell in a way the other route cannot. The two are different delivery problems rather than different strengths of the same product, and neither has outcome trials behind it.
Why do NAD+ drips take so long?
Because infusing NAD+ quickly commonly causes chest tightness, flushing, nausea and abdominal cramping. The infusion is run slowly to make it tolerable, and clinics generally describe this openly. It is a characteristic of the route rather than a hidden problem, and it is not presented here as a safety verdict. It does illustrate something about the pharmacology: the body reacts noticeably to this material rather than absorbing it quietly, which sits awkwardly with the idea of simply topping up a tank.
Is the injection just a scaled-down drip?
It is a different route with less published human evidence behind it, not a scaled-down version of the same thing. Its practical selling point is that it removes the clinic session. The published literature specific to subcutaneous or intramuscular NAD+ is thin, and most of what is claimed for it is inferred from the intravenous work plus the general pharmacology of the molecule. That is a chain of reasoning rather than a finding, and it should be read as one.
Why are both graded limited if neither has outcome evidence?
Because the grade is set at the level of the compound category, and it is carried by the oral precursors. Human trials of nicotinamide riboside have repeatedly shown that taking it raises measurable NAD+ levels in blood in a dose-related way, which is the strongest replicated finding in this category. That data is about capsules. Both injectable routes inherit the category grade without having earned it, and that is stated plainly rather than left to imply support the routes do not have.
Is there evidence that either route helps with addiction or withdrawal?
This is the most aggressively marketed use of intravenous NAD+ and the one with the widest gap between the advertising and the published record. The human work on intravenous NAD+ has been small, and it has largely examined what happens to the molecule in the body rather than whether patients do better. No body of adequately controlled outcome trials has been published establishing benefit for this use. The injectable route inherits the claim without adding evidence to it.
Do NAD+ levels in a blood test show which route worked?
A blood level shows that material was delivered and is being processed, which is not the same as a benefit. The category’s established finding is that NAD+ availability can be raised in people, most clearly with oral precursors. What has not been shown reliably is that raising it produces the energy, cognitive or recovery outcomes the category is sold on. Comparing two blood results across routes tells you about delivery. It does not tell you which route helped, because that question has not been answered for either one.